Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...
The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.
In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...
Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for ...
BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti ® (denosumab subcutaneous injection, ...
WASHINGTON, DC, USA, August 22, 2023/EINPresswire.com/ -- The US Drug Watchdog is a consumer advocate for consumers in the United States and they are focused in on ...
Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...
The FDA has approved Bosaya and Aukelso, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...
India-based Biocon’s biosimilars subsidiary has reached a settlement and license agreement with Amgen that clears the path ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback